Monoclonal antibodies in neurology: current state and future development
Monoclonal antibodies are one of the most fastly developing areas of specific therapy for cancer, infectious, autoimmune and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B-lymphocytes, cytokines, complement, and adhesion molecul...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2018-12-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/568/458 |
| _version_ | 1818230697798664192 |
|---|---|
| author | Maria N. Zakharova |
| author_facet | Maria N. Zakharova |
| author_sort | Maria N. Zakharova |
| collection | DOAJ |
| description | Monoclonal antibodies are one of the most fastly developing areas of specific therapy for cancer, infectious, autoimmune and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B-lymphocytes, cytokines, complement, and adhesion molecules. In the field of neurodegenerative diseases, the largest number of studies has been carried out in patients with Alzheimer's disease, in which monoclonal antibodies are targeted to brain aggregates of beta-amyloid. This review presents new therapeutic approaches to the use of antibody fragments, with a focus of their new class, nanobodies. A special attention is paid to new anti-CD20 and anti-CD19 monoclonal antibody drugs in multiple sclerosis (ocrelizumab, ofatumumab) and neuromyelitis optica (inebilizumab). Ocrelizumab is the first medication that proved to be effective in primary progressive multiple sclerosis. There have been significant advances in the treatment of neuromyelitis optica: the first multicenter study of Inebilizumab (MEDI-551) is currently underway. |
| first_indexed | 2024-12-12T10:38:37Z |
| format | Article |
| id | doaj.art-ae6f57eb014e454183f9e1d22b723916 |
| institution | Directory Open Access Journal |
| issn | 2075-5473 2409-2533 |
| language | English |
| last_indexed | 2024-12-12T10:38:37Z |
| publishDate | 2018-12-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj.art-ae6f57eb014e454183f9e1d22b7239162022-12-22T00:27:07ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332018-12-01125S9910410.25692/ACEN.2018.5.13439Monoclonal antibodies in neurology: current state and future developmentMaria N. Zakharova0Research Center of NeurologyMonoclonal antibodies are one of the most fastly developing areas of specific therapy for cancer, infectious, autoimmune and demyelinating diseases. The main targets of monoclonal antibodies in autoimmune and demyelinating diseases are T and B-lymphocytes, cytokines, complement, and adhesion molecules. In the field of neurodegenerative diseases, the largest number of studies has been carried out in patients with Alzheimer's disease, in which monoclonal antibodies are targeted to brain aggregates of beta-amyloid. This review presents new therapeutic approaches to the use of antibody fragments, with a focus of their new class, nanobodies. A special attention is paid to new anti-CD20 and anti-CD19 monoclonal antibody drugs in multiple sclerosis (ocrelizumab, ofatumumab) and neuromyelitis optica (inebilizumab). Ocrelizumab is the first medication that proved to be effective in primary progressive multiple sclerosis. There have been significant advances in the treatment of neuromyelitis optica: the first multicenter study of Inebilizumab (MEDI-551) is currently underway.https://annaly-nevrologii.com/journal/pathID/article/viewFile/568/458multiple sclerosisdemyelinating diseasesneuromyeltitis opticaalzheimer’s diseasemonoclonal antibodiesnanobodies |
| spellingShingle | Maria N. Zakharova Monoclonal antibodies in neurology: current state and future development Анналы клинической и экспериментальной неврологии multiple sclerosis demyelinating diseases neuromyeltitis optica alzheimer’s disease monoclonal antibodies nanobodies |
| title | Monoclonal antibodies in neurology: current state and future development |
| title_full | Monoclonal antibodies in neurology: current state and future development |
| title_fullStr | Monoclonal antibodies in neurology: current state and future development |
| title_full_unstemmed | Monoclonal antibodies in neurology: current state and future development |
| title_short | Monoclonal antibodies in neurology: current state and future development |
| title_sort | monoclonal antibodies in neurology current state and future development |
| topic | multiple sclerosis demyelinating diseases neuromyeltitis optica alzheimer’s disease monoclonal antibodies nanobodies |
| url | https://annaly-nevrologii.com/journal/pathID/article/viewFile/568/458 |
| work_keys_str_mv | AT marianzakharova monoclonalantibodiesinneurologycurrentstateandfuturedevelopment |